As the ‘miracle’ drugs sweep the globe, pubs, bars and drinks manufacturers are scrambling to cope with an unexpected side ...

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will ...

On an adjusted basis, the U.S. drugmaker expects to earn between $22.50 and $24.00 per share in 2025. Analysts were expecting ...

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will be subject to the next round of Medicare price negotiations ...

LONDON/COPENHAGEN (Reuters) -Wegovy maker Novo Nordisk on Wednesday forecast slower sales growth for 2025 than 2024, a blow ...

The Biden administration moved Friday to negotiate the prices Medicare pays for the blockbuster weight-loss drugs Ozempic and Wegovy, medications costing the massive government health program ...

Ozempic, Wegovy and Other Drugs Are Among 15 Selected for Medicare's Price Negotiations WASHINGTON (AP) — Popular weight loss and diabetes drugs like Ozempic and Wegovy have been added to ...

In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current best-selling drug in this area, Wegovy, to shame. Let's look deeper into these ...

WEDNESDAY, Feb. 5, 2025 (HealthDay News) -- Hopes that GLP-1 drugs such as Ozempic and Wegovy could help slow Parkinson's ...